구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv) Johnson & Johnson·BCMA × CD3 132 trials·t½ ~2–3 weeks at steady state |
|---|---|
Overview Program | Tecvayli (teclistamab) |
Overview Company | Johnson & Johnson |
Overview Modality | ANTIBODY |
Overview Target | BCMA × CD3 |
Overview Indication | Relapsed or refractory multiple myeloma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. |
Positioning Known limitation | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. |
Positioning Development positioning | Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T. |
MoA Mechanism | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. |
MoA Biomarker | BCMA expression, MRD negativity, serum free light chain response. |
PK/PD Half-life | ~2–3 weeks at steady state |
PK/PD Species | Cynomolgus monkey, T-cell activation markers, cytokine profile, soluble BCMA |
PK/PD Animal (cat.) | Human, NHP |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. |
Toxicology CRS | CRS ~72%, grade ≥3 ~0.6% |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. |
Clinical Selected reported efficacy | ORR 63% |
Clinical Reported ORR | 63.0% |
Clinical Reported PFS | ~11.3 mo |
Clinical Result source | MajesTEC-1 (NCT03145181 / NCT04557098) |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03145181 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv) Johnson & Johnson·BCMA × CD3 132 trials·t½ ~2–3 weeks at steady state |
|---|---|
Overview Program | Tecvayli (teclistamab) |
Overview Company | Johnson & Johnson |
Overview Modality | ANTIBODY |
Overview Target | BCMA × CD3 |
Overview Indication | Relapsed or refractory multiple myeloma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. |
Positioning Known limitation | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. |
Positioning Development positioning | Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T. |
MoA Mechanism | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. |
MoA Biomarker | BCMA expression, MRD negativity, serum free light chain response. |
PK/PD Half-life | ~2–3 weeks at steady state |
PK/PD Species | Cynomolgus monkey, T-cell activation markers, cytokine profile, soluble BCMA |
PK/PD Animal (cat.) | Human, NHP |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. |
Toxicology CRS | CRS ~72%, grade ≥3 ~0.6% |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. |
Clinical Selected reported efficacy | ORR 63% |
Clinical Reported ORR | 63.0% |
Clinical Reported PFS | ~11.3 mo |
Clinical Result source | MajesTEC-1 (NCT03145181 / NCT04557098) |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03145181 |
추천 비교
추천 비교